Valuation

ABCLAbCellera Biologics

StockNasdaqカナダHealth careEU retail: available
1/10

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricABCLSector medianvs median
P/E—15.6 · n=8—
P/B4.22.3 · n=1483% above
P/S57.33.5 · n=111,534% above
EV/EBIT—16.9 · n=7—
Free-cash-flow yield−3.2%5.0% · n=12164% below
Dividend yield0.00%1.67% · n=58100% below
Return on equity−17.3%2.5% · n=14800% below
Return on invested capital−26.6%4.6% · n=11677% below
Gross margin—66.3% · n=8—

Value factor: 2 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

InstrumentP/EP/BEV/EBITFree-cash-flow yieldDividend yieldSmart Score
NVSNovartis AG20.06.116.96.3%3.2%10/10
SNYSanofi11.11.215.38.3%6.1%7/10
ALCAlcon31.81.425.25.6%0.6%5/10
BNTXBioNTech SE—1.0—1.4%0.0%—/10
STESTERIS26.32.919.84.4%0.9%7/10
ICLRICON plc307.91.456.66.8%0.0%3/10
CRSPCRISPR Therapeutics AG—2.8—−7.6%0.0%1/10
ZLABZai Lab Ltd—4.2—−5.5%0.0%1/10
AUPHAurinia Pharmaceuticals7.03.6——0.0%—/10
NVCRNovoCure Limited—4.8—−1.6%0.0%2/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 6月 2026 · filed 05 8月 2026